All News

Chronic myeloid leukemia (CML)usually can be managed as a chronic disease by therapies, including Gleevec (imatinib) or two newer drugs, Sprycel (dasatinib) or Tasigna (nilotinib).

For Hodgkin lymphoma patients who progress after a stem cell transplant, two new treatments may bring new hope.

In recent years, scientists discovered that an enzyme called CYP2D6 could possibly predict whether a patient would respond to the drug. Small studies aimed at confirming the predictive link, however, have been consistently inconsistent.

Adding Afinitor, an mTOR inhibitor, to tamoxifen helped women with metastatic breast cancer live about four months longer without their disease getting worse, according to a study presented Thursday at SABCS.

After a diagnosis of stage 3 breast cancer at age 32, Moana Papa embraced advocacy, traveling from her home in New Zealand to the San Antonio Breast Cancer Symposium to bring information back to her community.

Obese women with breast cancer are at higher risk for recurrence and death, but new findings suggest it may depend on cancer subtype.

In the NeoSphere study, various combinations of a new HER2-targeted agent called pertuzumab, Herceptin and chemothery were studied in early-stage breast cancer patients with encouraging results.

After breast cancer, clinical sexologist Sueann Mark, PhD, developed a program to help survivors regain their sexuality after cancer.

New studies start to pinpoint the best strategy for treating HER2-positive breast cancer before surgery and lay the groundwork for future clinical trials.

Two studies presented at SABCS offer a better understanding of what to do with the information sentinel lymph nodes provide.